| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 183.58 | 5.5% | 15.6% |
| Total Income | 183.58 | 5.5% | 15.6% |
| Expenditure | 194.15 | 19.6% | 2.1% |
| PBT | -12.45 | 82.0% | 64.4% |
| Net Profit | -15.66 | 78.0% | 61.0% |
| OPM | -5.75% | 32.98pp | 19.13pp |
| NPM | -8.53% | 32.34pp | 16.75pp |
| EPS | -0.13 | 79.0% | 63.9% |
NovoCure Reports Q2 2026 Financial Results with 16% Revenue Growth
23 Jul 2026 · 23 Jul, 4:31 pm
Summary
NovoCure announced its strongest quarter to date for Q2 2026, with record net revenues of $183.6 million, marking a 16% increase year-over-year, driven by an 18% rise in global active patients. The company also achieved a significant milestone with the CE Mark approval for Optune Pax® for pancreatic cancer. Gross margin improved to 78% from 74% in the prior year. Despite a net loss of $15.7 million, Adjusted EBITDA was positive at $10.8 million. Management expressed confidence in their ability to bring TTFields therapy to more patients and drive sustainable growth.
Key Highlights
- 1
Novocure reported record net revenues of $183.6 million for the second quarter of 2026, an increase of 16% year-over-year.
- 2
Global active patient growth across indications was 18%, contributing significantly to the revenue increase.
- 3
The company received CE Mark for Optune Pax® for the treatment of locally advanced pancreatic cancer, with Germany being the first market to launch in the EU.
- 4
As of June 30, 2026, there were more than 280 active patients on Optune Pax.
- 5
Gross margin for the quarter improved to 78% compared to 74% in the prior year, benefiting from a one-time tariff refund.
- 6
Net loss for the quarter was $15.7 million, with a loss per share of $0.13.
- 7
Adjusted EBITDA for the quarter was $10.8 million.
Management Comments
Frank Leonard
This was our strongest quarter to date, with record net revenues and active patients on therapy. We continue to launch our therapies in multiple markets allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability.
Informational and educational content only. Not investment advice.